AstraZeneca: Auriane Cano-Chancel as head of oncology


(CercleFinance.com) – AstraZeneca announces the appointment of Auriane Cano-Chancel as Head of Oncology at AstraZeneca France. She replaces Dana Vigier, appointed Global Commercial Vice-President of the Lynparza Franchise & DDR (seno-gynecological cancers).

Auriane Cano-Chancel will lead the strategy as well as the commercial and medical activities of the French oncology division of AstraZeneca.

With a portfolio of 12 approved treatments and 25 molecules in development in France, AstraZeneca aims to double the 5-year survival rate in 5 tumors and thus tend towards the cure of cancers in the long term.

‘AstraZeneca has always been a pioneer in precision medicine, and leverages the diversity of its therapeutic platforms to tackle the various causes of cancer’, points out Auriane Cano-Chancel.

An engineer by training and a graduate of an MBA in Biosciences from the University of Cambridge, Auriane has been working in the pharmaceutical industry for more than 10 years.

‘France has an unprecedented commitment to the fight against cancer. Access to our molecules is one of our priorities and must be facilitated for every French patient,” she concludes.

Copyright © 2022 CercleFinance.com. All rights reserved.

Did you like this article ? Share it with your friends with the buttons below.





Facebook


LinkedIn


E-mail





Source link -85